Jenni Hietanen1, Anongruk Chim-Ong1, Jetsumon Sattabongkot2, Wang Nguitragool3. 1. Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, 10400, Bangkok, Thailand. 2. Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, 10400, Bangkok, Thailand. 3. Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University, 420/6 Ratchawithi Road, Ratchathewi, 10400, Bangkok, Thailand. wang.ngu@mahidol.edu.
Abstract
BACKGROUND: Plasmodium vivax is the most prevalent malaria parasite in many countries. A better understanding of human immunity to this parasite can provide new insights for vaccine development. Plasmodium vivax Reticulocyte Binding Proteins (RBPs) are key parasite proteins that interact with human proteins during erythrocyte invasion and are targets of the human immune response. The aim of this study is to characterize the human antibody response to RBP2P1, the most recently described member of the RBP family. METHODS: The levels of total IgG and IgM against RBP2P1 were measured using plasmas from 68 P. vivax malaria patients and 525 villagers in a malarious village of western Thailand. The latter group comprises asymptomatic carriers and healthy uninfected individuals. Subsets of plasma samples were evaluated for anti-RBP2P1 IgG subtypes and complement-fixing activity. RESULTS: As age increased, it was found that the level of anti-RBP2P1 IgG increased while the level of IgM decreased. The main anti-RBP2P1 IgG subtypes were IgG1 and IgG3. The IgG3-seropositive rate was higher in asymptomatic carriers than in patients. The higher level of IgG3 was correlated with higher in vitro RBP2P1-mediated complement fixing activity. CONCLUSIONS: In natural infection, the primary IgG response to RBP2P1 was IgG1 and IgG3. The predominance of these cytophilic subtypes and the elevated level of IgG3 correlating with complement fixing activity, suggest a possible role of anti-RBP2P1 antibodies in immunity against P. vivax.
BACKGROUND:Plasmodium vivax is the most prevalent malaria parasite in many countries. A better understanding of human immunity to this parasite can provide new insights for vaccine development. Plasmodium vivax Reticulocyte Binding Proteins (RBPs) are key parasite proteins that interact with human proteins during erythrocyte invasion and are targets of the human immune response. The aim of this study is to characterize the human antibody response to RBP2P1, the most recently described member of the RBP family. METHODS: The levels of total IgG and IgM against RBP2P1 were measured using plasmas from 68 P. vivax malariapatients and 525 villagers in a malarious village of western Thailand. The latter group comprises asymptomatic carriers and healthy uninfected individuals. Subsets of plasma samples were evaluated for anti-RBP2P1 IgG subtypes and complement-fixing activity. RESULTS: As age increased, it was found that the level of anti-RBP2P1 IgG increased while the level of IgM decreased. The main anti-RBP2P1 IgG subtypes were IgG1 and IgG3. The IgG3-seropositive rate was higher in asymptomatic carriers than in patients. The higher level of IgG3 was correlated with higher in vitro RBP2P1-mediated complement fixing activity. CONCLUSIONS: In natural infection, the primary IgG response to RBP2P1 was IgG1 and IgG3. The predominance of these cytophilic subtypes and the elevated level of IgG3 correlating with complement fixing activity, suggest a possible role of anti-RBP2P1 antibodies in immunity against P. vivax.
Authors: James G Beeson; Liriye Kurtovic; Carlota Dobaño; D Herbert Opi; Jo-Anne Chan; Gaoqian Feng; Michael F Good; Linda Reiling; Michelle J Boyle Journal: Sci Transl Med Date: 2019-01-09 Impact factor: 17.956
Authors: F Ellis Mckenzie; Chansuda Wongsrichanalai; Alan J Magill; J Russ Forney; Barnyen Permpanich; Carmen Lucas; Laura M Erhart; Wendy P O'Meara; David L Smith; Jeeraphat Sirichaisinthop; Robert A Gasser Journal: J Parasitol Date: 2006-12 Impact factor: 1.276
Authors: Camila Tenorio França; Michael T White; Wen-Qiang He; Jessica B Hostetler; Jessica Brewster; Gabriel Frato; Indu Malhotra; Jakub Gruszczyk; Christele Huon; Enmoore Lin; Benson Kiniboro; Anjali Yadava; Peter Siba; Mary R Galinski; Julie Healer; Chetan Chitnis; Alan F Cowman; Eizo Takashima; Takafumi Tsuboi; Wai-Hong Tham; Rick M Fairhurst; Julian C Rayner; Christopher L King; Ivo Mueller Journal: Elife Date: 2017-09-26 Impact factor: 8.140
Authors: Julia C Cutts; Rosanna Powell; Paul A Agius; James G Beeson; Julie A Simpson; Freya J I Fowkes Journal: BMC Med Date: 2014-09-09 Impact factor: 8.775
Authors: Camila T França; Wen-Qiang He; Jakub Gruszczyk; Nicholas T Y Lim; Enmoore Lin; Benson Kiniboro; Peter M Siba; Wai-Hong Tham; Ivo Mueller Journal: PLoS Negl Trop Dis Date: 2016-09-27